Ep. 404: "The Promise, The Potential, and the Pressing Questions Facing Multi-Cancer Early Detection (MCED) Testing" - Tom Beer, M.D.
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
概要
On this episode of "Halteres Presents", hosts Mickey Urdea and Rich Thayer are sitting down with Dr. Tom Beer, Vice President and Chief Medical Officer of Multi-Cancer Early Detection at Exact Sciences, to discuss all things MCEDs - the most impactful attributes of a successful MCED test, the consumer education efforts made by Exact Sciences, and what it was like to see Woody Harrelson lampoon the Cologuard test on SNL. Please enjoy this episode of "Halteres Presents".
Tomasz (Tom) Beer, M.D. earned his bachelor’s degree in biomedical engineering and his M.D. degree from Johns Hopkins University. He completed his post-graduate training in internal medicine, hematology, and medical oncology at Oregon Health & Science University. Dr. Beer has served as the vice president and chief medical officer, for multi-cancer early detection at Exact Sciences since 2022. Prior to joining Exact Sciences, Dr. Beer was the Grover C. Bagby Endowed Chair for Prostate Cancer Research at the OHSU Knight Cancer Institute, where he led the Prostate Cancer Research Program.
Dr. Beer also served as deputy director of the OHSU Knight Cancer Institute and the National Cancer Institute designated Comprehensive Cancer Center. He was previously the chief medical officer for the Center for Early Detection Advanced Research (CEDAR), where he led clinical trials of multi-omic blood-based cancer early detection tests.
Dr. Beer continues to serve as adjunct professor of medicine at the OHSU Knight Cancer Institute, where he treats men with prostate cancer. He has authored or co- authored more than 280 peer-reviewed articles, including investigations of multi-cancer early detection, as well as targeted therapies and immunotherapies in prostate cancer. Dr. Beer’s research served as the basis for a global change in the standard of care for advanced prostate cancer.
This episode of "Halteres Presents" is brought to you by the UC San Diego Division of Extended Studies, where courses are designed for professionals looking to deepen their expertise in the biotech space. Their core course, In Vitro Diagnostics Product Development, offers a practical, end-to-end look at taking an IVD product from concept to regulatory approval. You’ll learn about product requirements, assay development, instrumentation, risk analysis, and key clinical and regulatory considerations. Learn more about the In Vitro Diagnostics Product Development course HERE.
You can also broaden your skills with their Precision Medicine and Companion Diagnostics course, which covers biomarker-driven development, CDx/therapeutic co-development, and the expanding role of precision medicine. Learn more about the Precision Medicine and Companion Diagnostics course HERE.
Use our exclusive discount code HALTERES10 at checkout for 10% off the price of your enrollment.
Advance your diagnostics career with UC San Diego Extended Studies - your next step in biotech starts here.
Learn more about Halteres Associates HERE.